New drug combo shows promise for Hard-to-Treat lung cancer

NCT ID NCT05801029

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 20 times

Summary

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer with a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will receive the drug combination as their first treatment. The main goals are to check side effects and see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Hong Kong, 150001, Hong Kong
Research Site

Hong Kong, 999077, Hong Kong
Research Site

Hong Kong, Hong Kong
Research Site

Shatin, 00000, Hong Kong
Research Site

George Town, 10990, Malaysia
Research Site

Kota Bharu, 15586, Malaysia
Research Site

Kuala Lumpur, 50586, Malaysia
Research Site

Kuala Lumpur, 59100, Malaysia
Research Site

Kuantan, 25100, Malaysia
Research Site

Kuching, 93200, Malaysia
Research Site

Singapore, 169610, Singapore
Research Site

Singapore, 308433, Singapore
Research Site

Anyang-si, 14068, South Korea
Research Site

Busan, 49241, South Korea
Research Site

Daegu, 42415, South Korea
Research Site

Seoul, 08308, South Korea
Research Site

Seoul, 5030, South Korea
Research Site

Kaohsiung City, 82445, Taiwan
Research Site

Taichung, 404, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 73657, Taiwan
Research Site

Taipei, 10048, Taiwan
Research Site

Taipei, 110, Taiwan
Research Site

Yunlin, 640, Taiwan
Research Site

Bangkok, 10330, Thailand
Research Site

Bangkok, 10400, Thailand
Research Site

Bangkok, 10700, Thailand
Research Site

Chiang Mai, 50200, Thailand
Research Site

Songkhla, 90110, Thailand

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NSCLC NON-SMALL CELL LUNG CANCER (NSCLC)